Heart failure as a comorbidity of diabetes: Role of dipeptidyl peptidase 4

Journal of Atherosclerosis and Thrombosis

Volumn 23, Issue 2, 2016, Pages 147-154

  Bando, Yasuko K ^a   Murohara, Toyoaki ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Diabetes; Diabetic cardiomyopathy; Dipeptidyl peptidase 4; Heart failure

Indexed keywords

DIPEPTIDYL PEPTIDASE IV;

CARDIOVASCULAR DISEASE; COMORBIDITY; DIABETES MELLITUS; DIABETIC CARDIOMYOPATHY; DISEASE ASSOCIATION; ENZYME INHIBITION; GLUCOTOXICITY; HEART FAILURE; HEART MUSCLE FIBROSIS; HEART VENTRICLE HYPERTROPHY; HUMAN; LIPOTOXICITY; OXIDATIVE STRESS; REVIEW; ANIMAL; COMPLICATION; ENZYMOLOGY; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS;

ANIMALS; COMORBIDITY; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL PEPTIDASE 4; HEART FAILURE; HUMANS;

EID: 84957111573     PISSN: 13403478     EISSN: 18803873     Source Type: Journal    
DOI: 10.5551/jat.33225     Document Type: Review

References (70)

1. Leyden E: Asthma and diabetes mellitus. Zeutschr Klin Med, 1881; 3: 358-364
2. Asghar O, Al-Sunni A, Khavandi K, Khavandi A, Withers S, Greenstein A, Heagerty AM and Malik RA: Diabetic cardiomyopathy. Clin Sci (Lond), 2009; 116: 741-760
3. Rubler S, Dlugash J, Yuceoglu YZ, Kumral T, Branwood AW and Grishman A: New type of cardiomyopathy associated with diabetic glomerulosclerosis. The American journal of cardiology, 1972; 30: 595-602
4. Factor SM, Okun EM and Minase T: Capillary microaneurysms in the human diabetic heart. The New England journal of medicine, 1980; 302: 384-388
5. Ryden L, Grant PJ, Anker SD, Berne C, Cosentino F, Danchin N, Deaton C, Escaned J, Hammes HP, Huikuri H, Marre M, Marx N, Mellbin L, Ostergren J, Patrono C, Seferovic P, Uva MS, Taskinen MR, Tendera M, Tuomilehto J, Valensi P, Zamorano JL, Zamorano JL, Achenbach S, Baumgartner H, Bax JJ, Bueno H, Dean V, Deaton C, Erol C, Fagard R, Ferrari R, Hasdai D, Hoes AW, Kirchhof P, Knuuti J, Kolh P, Lancellotti P, Linhart A, Nihoyannopoulos P, Piepoli MF, Ponikowski P, Sirnes PA, Tamargo JL, Tendera M, Torbicki A, Wijns W, Windecker S, De Backer G, Sirnes PA, Ezquerra EA, Avogaro A, Badimon L, Baranova E, Baumgartner H, Betteridge J, Ceriello A, Fagard R, Funck-Brentano C, Gulba DC, Hasdai D, Hoes AW, Kjekshus JK, Knuuti J, Kolh P, Lev E, Mueller C, Neyses L, Nilsson PM, Perk J, Ponikowski P, Reiner Z, Sattar N, Schachinger V, Scheen A, Schirmer H, Stromberg A, Sudzhaeva S, Tamargo JL, Viigimaa M, Vlachopoulos C and Xuereb RG: ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). European heart journal, 2013; 34: 3035-3087
6. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Jr., Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJ, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WH, Tsai EJ and Wilkoff BL: 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Journal of the American College of Cardiology, 2013; 62: e147-239
7. Paulus WJ and Tschope C: A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. Journal of the American College of Cardiology, 2013; 62: 263- 271
8. Ho JE, Lyass A, Lee DS, Vasan RS, Kannel WB, Larson MG and Levy D: Predictors of new-onset heart failure: differences in preserved versus reduced ejection fraction. Circ Heart Fail, 2013; 6: 279-286
9. Loganathan R, Bilgen M, Al-Hafez B and Smirnova IV: Characterization of alterations in diabetic myocardial tissue using high resolution MRI. The international journal of cardiovascular imaging, 2006; 22: 81-90
10. Kwon DH, Smedira NG, Rodriguez ER, Tan C, Setser R, Thamilarasan M, Lytle BW, Lever HM and Desai MY: Cardiac magnetic resonance detection of myocardial scarring in hypertrophic cardiomyopathy: correlation with histopathology and prevalence of ventricular tachycardia. Journal of the American College of Cardiology, 2009; 54: 242-249
11. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC and Holman RR: Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ, 2000; 321: 405- 412
12. Higashimoto Y, Matsui T, Nishino Y, Taira J, Inoue H, Takeuchi M and Yamagishi SI: Blockade by phosphorothioate aptamers of advanced glycation end productsinduced damage in cultured pericytes and endothelial cells. Microvascular research, 2013;
13. Cheung N and Wong TY: Diabetic retinopathy and systemic vascular complications. Progress in retinal and eye research, 2008; 27: 161-176
14. Cheung N, Wang JJ, Rogers SL, Brancati F, Klein R, Sharrett AR and Wong TY: Diabetic retinopathy and risk of heart failure. Journal of the American College of Cardiology, 2008; 51: 1573-1578
15. Kurioka S, Ose H, Fukuma K and Yoshimoto K: Severity of diabetic retinopathy is associated with left ventricular diastolic dysfunction in patients with type 2 diabetes. Diabetes research and clinical practice, 2013; 99: 287-291
16. Takeda Y, Sakata Y, Mano T, Ohtani T, Tamaki S, Omori Y, Tsukamoto Y, Aizawa Y, Komuro I and Yamamoto K: Diabetic retinopathy is associated with impaired left ventricular relaxation. Journal of cardiac failure, 2011; 17: 556-560
17. Kawata T, Daimon M, Miyazaki S, Ichikawa R, Maruyama M, Chiang SJ, Ito C, Sato F, Watada H and Daida H: Coronary microvascular function is independently associated with left ventricular filling pressure in patients with type 2 diabetes mellitus. Cardiovascular diabetology, 2015; 14: 98
18. Fukami K, Yamagishi SI and Okuda S: Role of AGEs- RAGE system in cardiovascular disease. Current pharmaceutical design, 2013;
19. Tahara N, Yamagishi S, Takeuchi M, Tahara A, Kaifu K, Ueda S, Okuda S and Imaizumi T: Serum levels of advanced glycation end products (AGEs) are independently correlated with circulating levels of dipeptidyl peptidase- 4 (DPP-4) in humans. Clinical biochemistry, 2013; 46: 300-303
20. Hatano R, Ohnuma K, Yamamoto J, Dang NH and Morimoto C: CD26-mediated co-stimulation in human CD8(+) T cells provokes effector function via pro-inflammatory cytokine production. Immunology, 2013; 138: 165-172
21. Zhong J, Rao X and Rajagopalan S: An emerging role of dipeptidyl peptidase 4 (DPP4) beyond glucose control: potential implications in cardiovascular disease. Atherosclerosis, 2013; 226: 305-314
22. Murohara T: Dipeptidyl peptidase-4 inhibitor: another player for cardiovascular protection. Journal of the American College of Cardiology, 2012; 59: 277-279
23. Matheeussen V, Jungraithmayr W and De Meester I: Dipeptidyl peptidase 4 as a therapeutic target in ischemia/ reperfusion injury. Pharmacology & therapeutics, 2012; 136: 267-282
24. Shigeta T, Aoyama M, Bando YK, Monji A, Mitsui T, Takatsu M, Cheng XW, Okumura T, Hirashiki A, Nagata K and Murohara T: Dipeptidyl peptidase-4 modulates left ventricular dysfunction in chronic heart failure via angiogenesis- dependent and -independent actions. Circulation, 2012; 126: 1838-1851
25. Lee SA, Kim YR, Yang EJ, Kwon EJ, Kim SH, Kang SH, Park DB, Oh BC, Kim J, Heo ST, Koh G and Lee DH: CD26/DPP4 levels in peripheral blood and T cells in patients with type 2 diabetes mellitus. The Journal of clinical endocrinology and metabolism, 2013; 98: 2553- 2561
26. Matsubara J, Sugiyama S, Akiyama E, Iwashita S, Kurokawa H, Ohba K, Maeda H, Fujisue K, Yamamoto E, Kaikita K, Hokimoto S, Jinnouchi H and Ogawa H: Dipeptidyl peptidase-4 inhibitor, sitagliptin, improves endothelial dysfunction in association with its antiinflammatory effects in patients with coronary artery disease and uncontrolled diabetes. Circ J, 2013; 77: 1337- 1344
27. Makdissi A, Ghanim H, Vora M, Green K, Abuaysheh S, Chaudhuri A, Dhindsa S and Dandona P: Sitagliptin exerts an antinflammatory action. The Journal of clinical endocrinology and metabolism, 2012; 97: 3333-3341
28. Boudina S and Abel ED: Diabetic cardiomyopathy revisited. Circulation, 2007; 115: 3213-3223
29. Poornima IG, Parikh P and Shannon RP: Diabetic cardiomyopathy: the search for a unifying hypothesis. Circulation research, 2006; 98: 596-605
30. Hu P, Zhang D, Swenson L, Chakrabarti G, Abel ED and Litwin SE: Minimally invasive aortic banding in mice: effects of altered cardiomyocyte insulin signaling during pressure overload. American journal of physiology Heart and circulatory physiology, 2003; 285: H1261-1269
31. Doenst T, Nguyen TD and Abel ED: Cardiac metabolism in heart failure: implications beyond ATP production. Circulation research, 2013; 113: 709-724
32. Parra V, Verdejo HE, Iglewski M, Campo AD, Troncoso R, Jones D, Zhu Y, Kuzmicic J, Pennanen C, Lopez- Crisosto C, Jana F, Ferreira J, Noguera E, Chiong M, Bernlohr DA, Klip A, Hill JA, Rothermel BA, Abel ED, Zorzano A and Lavandero S: Insulin stimulates mitochondrial fusion and function in cardiomyocytes via the AktmTOR- NFkappaB-Opa-1 signaling pathway. Diabetes, 2013;
33. Abel ED, O'Shea KM and Ramasamy R: Insulin resistance: metabolic mechanisms and consequences in the heart. Arteriosclerosis, thrombosis, and vascular biology, 2012; 32: 2068-2076
34. Shimizu I, Minamino T, Toko H, Okada S, Ikeda H, Yasuda N, Tateno K, Moriya J, Yokoyama M, Nojima A, Koh GY, Akazawa H, Shiojima I, Kahn CR, Abel ED and Komuro I: Excessive cardiac insulin signaling exacerbates systolic dysfunction induced by pressure overload in rodents. The Journal of clinical investigation, 2010; 120: 1506-1514
35. Monji A, Mitsui T, Bando YK, Aoyama M, Shigeta T and Murohara T: Glucagon-like peptide-1 receptor activation reverses cardiac remodeling via normalizing cardiac steatosis and oxidative stress in type 2 diabetes. American journal of physiology Heart and circulatory physiology, 2013; 305: H295-304
36. Ramirez E, Klett-Mingo M, Ares-Carrasco S, Picatoste B, Ferrarini A, Ruperez FJ, Caro-Vadillo A, Barbas C, Egido J, Tunon J and Lorenzo O: Eplerenone attenuated cardiac steatosis, apoptosis and diastolic dysfunction in experimental type-II diabetes. Cardiovascular diabetology, 2013; 12: 172
37. Noyan-Ashraf MH, Shikatani EA, Schuiki I, Mukovozov I, Wu J, Li RK, Volchuk A, Robinson LA, Billia F, Drucker DJ and Husain M: A glucagon-like peptide-1 analog reverses the molecular pathology and cardiac dysfunction of a mouse model of obesity. Circulation, 2013; 127: 74-85
38. McGavock JM, Lingvay I, Zib I, Tillery T, Salas N, Unger R, Levine BD, Raskin P, Victor RG and Szczepaniak LS: Cardiac steatosis in diabetes mellitus: a 1H-magnetic resonance spectroscopy study. Circulation, 2007; 116: 1170- 1175
39. Rijzewijk LJ, van der Meer RW, Smit JW, Diamant M, Bax JJ, Hammer S, Romijn JA, de Roos A and Lamb HJ: Myocardial steatosis is an independent predictor of diastolic dysfunction in type 2 diabetes mellitus. Journal of the American College of Cardiology, 2008; 52: 1793- 1799
40. Lan HY: Transforming growth factor-beta/Smad signalling in diabetic nephropathy. Clinical and experimental pharmacology & physiology, 2012; 39: 731-738
41. Asbun J and Villarreal FJ: The pathogenesis of myocardial fibrosis in the setting of diabetic cardiomyopathy. Journal of the American College of Cardiology, 2006; 47: 693- 700
42. Zieman S and Kass D: Advanced glycation end product cross-linking: pathophysiologic role and therapeutic target in cardiovascular disease. Congest Heart Fail, 2004; 10: 144-149; quiz 150-141
43. Cieslik KA, Trial J, Carlson S, Taffet GE and Entman ML: Aberrant differentiation of fibroblast progenitors contributes to fibrosis in the aged murine heart: role of elevated circulating insulin levels. FASEB journal: official publication of the Federation of American Societies for Experimental Biology, 2013; 27: 1761-1771
44. Van Linthout S, Seeland U, Riad A, Eckhardt O, Hohl M, Dhayat N, Richter U, Fischer JW, Bohm M, Pauschinger M, Schultheiss HP and Tschope C: Reduced MMP-2 activity contributes to cardiac fibrosis in experimental diabetic cardiomyopathy. Basic research in cardiology, 2008; 103: 319-327
45. Kaji K, Yoshiji H, Ikenaka Y, Noguchi R, Aihara Y, Douhara A, Moriya K, Kawaratani H, Shirai Y, Yoshii J, Yanase K, Kitade M, Namisaki T and Fukui H: Dipeptidyl peptidase-4 inhibitor attenuates hepatic fibrosis via suppression of activated hepatic stellate cell in rats. Journal of gastroenterology, 2014; 49: 481-491
46. Panchapakesan U and Pollock C: The Role of Dipeptidyl Peptidase - 4 Inhibitors in Diabetic Kidney Disease. Frontiers in immunology, 2015; 6: 443
47. Keane FM, Nadvi NA, Yao TW and Gorrell MD: Neuropeptide Y, B-type natriuretic peptide, substance P and peptide YY are novel substrates of fibroblast activation protein-alpha. The FEBS journal, 2011; 278: 1316-1332
48. Davi G, Catalano I, Averna M, Notarbartolo A, Strano A, Ciabattoni G and Patrono C: Thromboxane biosynthesis and platelet function in type II diabetes mellitus. The New England journal of medicine, 1990; 322: 1769-1774
49. Spectre G, Ostenson CG, Li N and Hjemdahl P: Postprandial platelet activation is related to postprandial plasma insulin rather than glucose in patients with type 2 diabetes. Diabetes, 2012; 61: 2380-2384
50. Santilli F, Formoso G, Sbraccia P, Averna M, Miccoli R, Di Fulvio P, Ganci A, Pulizzi N, Lattanzio S, Ciabattoni G, Consoli A, Lauro R, Patrono C and Davi G: Postprandial hyperglycemia is a determinant of platelet activation in early type 2 diabetes mellitus. Journal of thrombosis and haemostasis: JTH, 2010; 8: 828-837
51. Granger DN, Rodrigues SF, Yildirim A and Senchenkova EY: Microvascular responses to cardiovascular risk factors. Microcirculation, 2010; 17: 192-205
52. Brooks BA, Franjic B, Ban CR, Swaraj K, Yue DK, Celermajer DS and Twigg SM: Diastolic dysfunction and abnormalities of the microcirculation in type 2 diabetes. Diabetes, obesity & metabolism, 2008; 10: 739-746
53. Herrmann J, Kaski JC and Lerman A: Coronary microvascular dysfunction in the clinical setting: from mystery to reality. European heart journal, 2012; 33: 2771-2782b
54. Ogawa H, Nakayama M, Morimoto T, Uemura S, Kanauchi M, Doi N, Jinnouchi H, Sugiyama S and Saito Y: Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA: the journal of the American Medical Association, 2008; 300: 2134-2141
55. Cerbone AM, Macarone-Palmieri N, Saldalamacchia G, Coppola A, Di Minno G and Rivellese AA: Diabetes, vascular complications and antiplatelet therapy: open problems. Acta diabetologica, 2009; 46: 253-261
56. Krijnen PA, Hahn NE, Kholova I, Baylan U, Sipkens JA, van Alphen FP, Vonk AB, Simsek S, Meischl C, Schalkwijk CG, van Buul JD, van Hinsbergh VW and Niessen HW: Loss of DPP4 activity is related to a prothrombogenic status of endothelial cells: implications for the coronary microvasculature of myocardial infarction patients. Basic research in cardiology, 2012; 107: 233
57. Borlaug BA and Paulus WJ: Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment. European heart journal, 2011; 32: 670-679
58. Lane DJ, Huang ML, Ting S, Sivagurunathan S and Richardson DR: Biochemistry of cardiomyopathy in the mitochondrial disease Friedreich's ataxia. The Biochemical journal, 2013; 453: 321-336
59. Faden G, Faganello G, De Feo S, Berlinghieri N, Tarantini L, Di Lenarda A, Faggiano P and Cioffi G: The increasing detection of asymptomatic left ventricular dysfunction in patients with type 2 diabetes mellitus without overt cardiac disease: data from the SHORTWAVE study. Diabetes research and clinical practice, 2013; 101: 309- 316
60. Ernande L, Rietzschel ER, Bergerot C, De Buyzere ML, Schnell F, Groisne L, Ovize M, Croisille P, Moulin P, Gillebert TC and Derumeaux G: Impaired myocardial radial function in asymptomatic patients with type 2 diabetes mellitus: a speckle-tracking imaging study. Journal of the American Society of Echocardiography: official publication of the American Society of Echocardiography, 2010; 23: 1266-1272
61. Miki T, Yuda S, Kouzu H and Miura T: Diabetic cardiomyopathy: pathophysiology and clinical features. Heart failure reviews, 2013; 18: 149-166
62. Mentlein R: Cell-surface peptidases. Int Rev Cytol, 2004; 235: 165-213
63. Bando YK and Murohara T: Diabetes-related heart failure. Circ J, 2014; 78: 576-583
64. Scheen AJ: Cardiovascular effects of dipeptidyl peptidase- 4 inhibitors: from risk factors to clinical outcomes. Postgrad Med, 2013; 125: 7-20
65. Zannad F, Cannon CP, Cushman WC, Bakris GL, Menon V, Perez AT, Fleck PR, Mehta CR, Kupfer S, Wilson C, Lam H, White WB and Investigators E: Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet, 2015; 385: 2067-2076
66. Goldfine AB: Assessing the cardiovascular safety of diabetes therapies. The New England journal of medicine, 2008; 359: 1092-1095
67. Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, Ohman P, Frederich R, Wiviott SD, Hoffman EB, Cavender MA, Udell JA, Desai NR, Mosenzon O, McGuire DK, Ray KK, Leiter LA, Raz I, Committee S-TS and Investigators: Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. The New England journal of medicine, 2013; 369: 1317-1326
68. White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, Perez AT, Fleck PR, Mehta CR, Kupfer S, Wilson C, Cushman WC, Zannad F and Investigators E: Alogliptin after acute coronary syndrome in patients with type 2 diabetes. The New England journal of medicine, 2013; 369: 1327-1335
69. Scirica BM, Braunwald E, Raz I, Cavender MA, Morrow DA, Jarolim P, Udell JA, Mosenzon O, Im K, Umez-Eronini AA, Pollack PS, Hirshberg B, Frederich R, Lewis BS, McGuire DK, Davidson J, Steg PG, Bhatt DL, Committee S-TS and Investigators*: Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. Circulation, 2014; 130: 1579-1588
70. Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, Josse R, Kaufman KD, Koglin J, Korn S, Lachin JM, McGuire DK, Pencina MJ, Standl E, Stein PP, Suryawanshi S, Van de Werf F, Peterson ED, Holman RR and Group TS: Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. The New England journal of medicine, 2015; 373: 232-242